JEWISH KING JESUS IS COMING AT THE RAPTURE FOR US IN THE CLOUDS-DON'T MISS IT FOR THE WORLD.THE BIBLE TAKEN LITERALLY- WHEN THE PLAIN SENSE MAKES GOOD SENSE-SEEK NO OTHER SENSE-LEST YOU END UP IN NONSENSE.GET SAVED NOW- CALL ON JESUS TODAY.THE ONLY SAVIOR OF THE WHOLE EARTH - NO OTHER. 1 COR 15:23-JESUS THE FIRST FRUITS-CHRISTIANS RAPTURED TO JESUS-FIRST FRUITS OF THE SPIRIT-23 But every man in his own order: Christ the firstfruits; afterward they that are Christ’s at his coming.ROMANS 8:23 And not only they, but ourselves also, which have the firstfruits of the Spirit, even we ourselves groan within ourselves, waiting for the adoption, to wit, the redemption of our body.(THE PRE-TRIB RAPTURE)
THE
PATENTS TELL US EVERYTHING HOW THE COVID SCAM STARTED BACK IN 1965 AS A
BIOLOGICAL WEAPON TO ATTACK HUMANS.AND DEPOPULATE THE EARTH..
PFIZER FIRST SPIKE PROTENE PATENED IN 1990.
PFIZER SAID VACCINES DON'T WORK ON COVID BECAUSE IT MUTATES IN 1990.
DAVIDS SPEECH ON VIDEO
https://www.youtube.com/watch?v=EONkIQnhVj0
THE GREAT AWAKENING-THE COVID PLANDEMIC
https://www.infowars.com/posts/watch-the-great-awakening-documentary-exposing-covid-plandemic/
foreign
it is a it is a particularly interesting location for me to be sitting
today given that over a decade ago I sat in this very chair right here
in the European Union Parliament and at that time I warned the world of
what was coming during that conversation that was hosted at the time by
the green and EFA and a number of the other parties of the European
unions various representations we were having a conversation on whether
Europe should adopt the United States policy of allowing for the patents
on biologically derived materials and at the time I urge this body and I
urge people around the world that the weaponization of nature Against
Humanity had dire consequences tragically I sit here today with that
unfortunate line that I don't like to say which I told you so but the
fact of the matter is we're here not for a reprisal on past decisions
we're here to actually once again come to the face of the human
condition and ask the question who do we want to be what do we want
Humanity to look like and rather than seeing this as an exercise in
futility which is very easy from time to time when you're in the
position I'm in I actually see this not as an exercise in futility I see
this as one of the greatest opportunities that faces us because we now
have a public conversation which is now front and center in people's
minds when this was an esoteric conversation about biological patents
nobody cared but when that conversation came home then it became
something people can care about so I'm actually quite grateful for this
opportunity I thank the members of parliament for hosting this I thank
all of the translators who I apologize in advance I will use terminology
that is probably very difficult to translate so my apologies I'd also
like to acknowledge the fact that many of you are aware of my
involvement with this in large part due to the amazing work of my
wonderful wife Kim Martin who encouraged me at the very early days of
this pandemic to get on front of the camera and talk about all the
information that I had been sharing among very small groups around the
world and it was in fact her encouragement that put me in a place where
many of you have heard what I have to say ironically the world that I
came from that used to be very popular my CNBC and Bloomberg
presentations which were televised on mainstream media around the world
was an audience that I lost I I can confidently say covid diminished my
fame but I can also confidently say that I'd rather stand among the
people with whom I'm standing today than any of the folks that were part
of that previous world so this is a much better place to be my role
today is to set the stage for this conversation in a historical context
because this did not come in the last three years this did not come in
the last five or six years this actually is an ongoing question that
probably began here in Europe in the early stages of the mid 1900s but
certainly by 1913 1914 this conversation started right here in Central
Europe the pandemic that we alleged to have happen in the last few years
also did not happen overnight in fact the very specific pandemic using
coronavirus began in a very different time and we'll try to advance the
slides here with one of these things up there we go most of you don't
know that coronavirus as a model of a pathogen was isolated in 1965.
COVID STARTED IN FULL GEAR IN 1945 AFTER THE 1913 - 1914 START.
coronavirus
was identified in 1965 as one of the first infectious replicatable
viral models that could be used to modify a series of other experiences
of the human condition it was isolated Once Upon a Time associated with
the common cold but what's particularly interesting about its isolation
in 1965 was that it was immediately identified as a pathogen that could
be used and modified for a whole host of reasons and you heard me
correctly that was 1965 and by the way these slides are public domain
you're welcome to look at every single reference every comment that I
made is based on published material so do make sure that you look at
those references but in 1966 the very first COV coronavirus model was
used as a transatlantic biological experiment in human manipulation and
you heard the date 1966. I hope you're getting the point of what I'm
saying this is not an overnight thing this is actually something that's
been long in the making a year before I was born we had the first
transatlantic coronavirus data sharing experiment between the United
States and the United Kingdom and in 1967 the year I was born we did the
first human trials on inoculating people with modified Coronavirus
amazing 56 years ago the overnight success of a pathogen that's been 56
years in engineering and I want that to chill with all of you where were
we when we actually allowed in violation of biological and chemical
weapons treaties where were we as a human civilization when we thought
it was an acceptable thing to do to take a pathogen for the United
States and infect the world with it where was that conversation and what
should have been that conversation in 1967. that conversation wasn't
had ironically the common cold was turned into a chimera in the 1970s
and in 1975 1976 and 1977 we started figuring out how to modify
coronavirus by putting it into different animals pigs and dogs and not
surprisingly by the time we got to 1990 we found out that coronavirus as
a infectious agent was an industrial problem for two primary Industries
the industries of dogs and pigs dog breeders and pigs found that
coronavirus created gastrointestinal problems and that became the basis
for Pfizer's first Spike protein vaccine Patent filed are you ready for
this in 1990 did you hear what I just said 1990 operation warp speed I'm
sorry where's the warp and the speed Pfizer 1990 the very first Spike
protein vaccine for Coronavirus foreign isn't that fascinating isn't it
fascinating that we were we were told that well the spike protein is a
new thing we just found out that that's the problem no as a matter of
fact we didn't just find out it was not just now now the problem we
found that out in 1990 and filed the first patents on vaccines in 1990
for the spike protein of Coronavirus and who would have thought Pfizer
clearly the innocent organization that does nothing but promote human
health clearly Pfizer the organization that has not bought the votes in
this chamber and at every chamber of every government around the world
not that Pfizer certainly they wouldn't have had anything to do with
this but oh yes they did and in 1990 they found out that there was a
problem with vaccines they didn't work you know why they didn't work it
turns out the coronavirus is a very malleable model it transforms and it
changes and it mutates over time as a matter of fact every publication
on vaccines for Coronavirus from 1990 until 2018 every single
publication concluded that coronavirus escapes the vaccine impulse
because it modifies and mutates too quickly for vaccines to be effective
and since 1990 to 2018 that is the published science ladies and
gentlemen that's following the science following the science is their
own indictment of their own programs that said it doesn't work and there
are thousands of Publications to that effect not a few hundred and not
paid for by pharmaceutical companies these are Publications that are
independent scientific research that shows unequivocally including
efforts of the Chimera modifications made by Ralph Barrick in the
University of North Carolina Chapel Hill all of them show vaccines do
not work on Coronavirus that's the science and that science has never
been disputed but then we had an interesting development in 2002 and
this date is most important because in 2002 the University of North
Carolina Chapel Hill patented and I quote an infectious replication
defective clone of Coronavirus listen to those words infectious
replication defective what does that phrase actually mean for those of
you not familiar with language
INFECTIOUS REPLICATION DEFECTIVE MEANS.
let
me unpack it for you infectious replication defective means a weapon it
means something meant to Target an individual but not have collateral
damage to other individuals that's what infectious replication defective
means and that patent was filed in 2002 on work funded by niaid's
Anthony fauci from 1999 to 2002 and that work patented at the University
of North Carolina Chapel Hill mysteriously preceded SARS 1.0 by a year
Dave are you suggesting that SARS 1.0 wasn't from a wet Market in Wuhan
are you suggesting it might have come from a laboratory in the
University of North Carolina Chapel Hill no I'm not suggesting it I'm
telling you that's the facts we engineered SARS SARS is not a naturally
occurring phenomenon the naturally occurring phenomenon is called the
common cold it's called influenza-like illness it's called
gastroenteritis that's the naturally occurring Coronavirus SARS is the
research developed by humans weaponizing a life system model to actually
attack human beings and they patented it in 2002.[Applause] and in 2003
giant surprise the CDC filed the patent on coronavirus isolated from
humans in violation once again of biological and chemical weapons
treaties and laws that we have in the United States and I'm very very
precise on this the United States likes to talk about its rights and
everything else and the rule of law and all the nonsense that we like to
talk about but we don't ratify treaties about I don't know defending
humans we conspicuously avoid that we actually have a great track record
of advocating for human rights and then denying them when it comes to
actually being part of the International Community which is a slightly
problematic thing but let's get something very clear when the CDC in
April of 2003 filed the patent on SARS coronavirus isolated from humans
what did they do they downloaded a sequence from China and filed a
patent on it in the United States any of you familiar with biological
and chemical weapons treaties knows that's a violation that's a crime
that's not an innocent oops that's a crime and the United States patent
office went as far as to reject that patent application on two occasions
until the CDC decided to bribe the patent office to override the patent
examiner to ultimately issue the patent in 2007 on SARS coronavirus but
let's not let that get away from us because it turns out that the rtpcr
which was the test that we allegedly were going to use to identify the
risks associated with Coronavirus was actually identified as a
bioterrorism threat by me in the European union-sponsored events in 2002
and 2003.20 years ago that happened here in Brussels and across Europe
in 2005 this particular pathogen was specifically labeled as a
bioterrorism and bioweapon platform technology described as such that's
not my terminology that I'm applying to it it was actually described as a
bioweapons platform technology in 2005.and from 2005 onwards it was
actually a bio Warfare enabling agent its official classification from
2005 forward I don't know if that sounds like public health to you does
it biological warfare enabling technology that feels like not Public
Health that feels like not medicine that feels like a weapon designed to
take out Humanity that's what it feels like and it feels like that
because that's exactly what is we have been lured into believing that
Eco Health Alliance and DARPA and all of these organizations are what we
should be pointing to but we've been specifically requested to ignore
the facts that over 10 billion dollars have been funneled through Black
Operations through the check of Anthony fauci and a side-by-side Ledger
where niaid has a balance sheet and next to it is a biodefense balance
sheet equivalent dollar for dollar matching that no one in the media
talks about and it's been going on since 2005.our gain of function
moratorium the moratorium That was supposed to freeze any efforts to do
gain a function research conveniently in the fall of 2014 the University
of North Carolina Chapel Hill received a letter from niid saying that
while the gain of function moratorium on coronavirus in Vivo should be
suspended because their grants had already been funded they received an
exemption did you hear what I just said a biological weapons lab
facility at the University of North Carolina Chapel Hill received an
exemption from the gain of function moratorium so that by 2016 we could
publish the the journal article that said SARS coronavirus is poised for
human emergence in 2016
WAS THE CORONAVIRUS POISED FOR HUMAN EMERGENCE.
and
what you might ask Dave was the coronavirus poised for human emergence
it was w i v one Wuhan Institute of virology virus 1.poised for human
emergence in 2016. at the proceedings of the National Academy of
Sciences such that by the time we get to 2017 and 2018 the following
phrase entered into common parlance among the community there is going
to be an accidental or intentional release of a respiratory pathogen the
operative word obviously in that phrase the word release does that
sound like leak does that sound like a bat and a Pangolin went into a
bar in the Wuhan market and hung out and had sex and and lo and behold
we got SARS cov2 no accidental or intentional release of a respiratory
pathogen was the terminology used and four times in April of 2019.seven
months before the allegation of patient number one four patent
applications of moderna were modified to include the term accidental or
intentional release of a respiratory pathogen as the justification for
making a vaccine for a thing that did not exist keep going if you have
not done so please make sure that you make reference in every
investigation to the premeditation nature of this because it was in
September of 2019 that the world was informed that we were going to have
an accident or intentional release of a respiratory pathogen so that by
September 2020 there would be a worldwide acceptance of a universal
vaccine template that's their words right in front of you on the screen
the intent was to get the world to accept a universal vaccine template
and the intent was to use coronavirus to get there and the last slide
this is an advancing so if I could have somebody to do it let's let's
read this because we have to read this into the record everywhere I go
until an infectious disease crisis is very real present and at the
emergency threshold that is often largely ignored to sustain the funding
base beyond the crisis he said we need to increase the public
understanding for the need for medical countermeasures such as a pan
influenza or pan coronavirus vaccine a key driver is the media and the
economics will follow the hype we need to use that hype to our advantage
to get to the real issues investors will respond if they see profit at
the end of the process.
ANTHONY
FAUCCI, BILL GATES AND ALL LAME BRAIN PROPAGANDA MEDIA INVOLVED WITH
COVID ARE DOMESTIC TERRORISTS USING CHEMICAL AND BIOLOGICAL WEAPONS ON
EARTHS POPULATION FOR OR MONEY AND DEPOPULISING THE WORLD.
sounds
like Public Health sounds like the best of humanity no ladies and
gentlemen this was premeditated domestic terrorism stated at the
proceedings of the National Academy of Sciences in 2015 published in
front of them this is an this is an act of biological and chemical
warfare perpetrated on the human race and it wasadmitted to in writing
that this was a financial Heist and a financial fraud investors will
follow if they see profit at the end of the process let me conclude by
making five very brief recommendations the last slide foreign nature was
hijacked this whole story started in 1965 when we decided to hijack a
natural model and decide to start manipulating it science was hijacked
when the only questions that could be asked were questions authorized
under the patent protection of the CDC the FDA the NIH and their
equivalent organizations around the world we didn't have independent
science we had hijacked science and unfortunately it was no moral
oversight in violation of all of the codes that we stand for there was
no independent financially disinterested independent review board ever
impaneled around coronavirus not once not once not since 1965.we do not
have a single independent IRB ever impaneled around coronavirus so
morality was suspended for medical countermeasures and ultimately
Humanity was lost because we decided to allow it to happen our job today
is to say no more gain of function research period no more
weaponization of nature period foreign most importantly no more
corporate patronage of science for their own self-interest unless they
assume 100 product liability for every injury and every death that they
maintain thank you very much foreign DAVID MARTIN OF THE EUROPEAN UNION GOVERNMENT.
THANK
YOU DAVE MARTIN FOR REVEALING THIS MONEY, DEPOPULATION, DOMESTIC
TERRORIST KILLER VACCINE SCAM THAT STARTED BACK IN 1965.THE PATENTS DO
TELL THE STORY OF THESE SLITHERING DEMONIC SNAKES FACCI, BILL GATES AND
DEMOLIBNUT MEDIA PROPAGANDISTS PAID WHORES.
PFIZER PATENTS
https://patents.justia.com/search?q=PFIZER+PATENTS
COVID PATENTS
https://patents.justia.com/search?q=COVID+PATENTS
COVID VACCINE PATENTS
https://patents.justia.com/search?q=COVID+VACCINE+PATENTS
Patents by Inventor Anthony S. Fauci
Anthony
S. Fauci has filed for patents to protect the following inventions.
This listing includes patent applications that are pending as well as
patents that have already been granted by the United States Patent and
Trademark Office (USPTO).
Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
Patent number: 9896509
Abstract: Methods are provided for the treatment of a HIV infection.
The methods can include administering to a subject with an HIV infection
a therapeutically effective amount of an agent that interferes with the
interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin
antagonist, thereby treating the HIV infection. In several examples, the
?4 integrin antagonist is a monoclonal antibody that specifically binds
to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the
amino acid sequence of CWLDVC. Methods are also provided to reduce HIV
replication or infection. The methods include contacting a cell with an
effective amount of an agent that interferes with the interaction of
gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist.
Moreover, methods are provided for determining if an agent is useful to
treat HIV.
Type: Grant
Filed: August 3, 2016
Date of Patent: February 20, 2018
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN
Publication number: 20160333097
Abstract: Methods are provided for the treatment of a HIV infection.
The methods can include administering to a subject with an HIV infection
a therapeutically effective amount of an agent that interferes with the
interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin
antagonist, thereby treating the HIV infection. In several examples, the
?4 integrin antagonist is a monoclonal antibody that specifically binds
to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the
amino acid sequence of CWLDVC. Methods are also provided to reduce HIV
replication or infection. The methods include contacting a cell with an
effective amount of an agent that interferes with the interaction of
gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist.
Moreover, methods are provided for determining if an agent is useful to
treat HIV.
Type: Application
Filed: August 3, 2016
Publication date: November 17, 2016
Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
Patent number: 9441041
Abstract: Methods are provided for the treatment of a HIV infection.
The methods can include administering to a subject with an HIV infection
a therapeutically effective amount of an agent that interferes with the
interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin
antagonist, thereby treating the HIV infection. In several examples, the
?4 integrin antagonist is a monoclonal antibody that specifically binds
to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the
amino acid sequence of CWLDVC. Methods are also provided to reduce HIV
replication or infection. The methods include contacting a cell with an
effective amount of an agent that interferes with the interaction of
gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist.
Moreover, methods are provided for determining if an agent is useful to
treat HIV.
Type: Grant
Filed: September 21, 2015
Date of Patent: September 13, 2016
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN
Publication number: 20160075786
Abstract: Methods are provided for the treatment of a HIV infection.
The methods can include administering to a subject with an HIV infection
a therapeutically effective amount of an agent that interferes with the
interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin
antagonist, thereby treating the HIV infection. In several examples, the
?4 integrin antagonist is a monoclonal antibody that specifically binds
to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the
amino acid sequence of CWLDVC. Methods are also provided to reduce HIV
replication or infection. The methods include contacting a cell with an
effective amount of an agent that interferes with the interaction of
gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist.
Moreover, methods are provided for determining if an agent is useful to
treat HIV.
Type: Application
Filed: September 21, 2015
Publication date: March 17, 2016
Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION
Publication number: 20090285815
Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are
disclosed herein that include a CD4 polypeptide ligated at its
C-terminus with a portion of an immunoglobulin comprising a hinge region
and a constant domain of a mammalian immunoglobulin heavy chain. The
portion of the IgG is fused at its C-terminus with a polypeptide
comprising a tailpiece from the C terminus of the heavy chain of an IgA
antibody or a tailpiece from a C terminus of the heavy chain of an IgM
antibody. Also disclosed herein are methods for using these CD4-fusion
proteins.
Type: Application
Filed: March 21, 2008
Publication date: November 19, 2009
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
Fusion protein including of CD4
Patent number: 7368114
Abstract: Novel recombinant polypeptides are disclosed herein that
include a CD4 polypeptide ligated at its C-terminus with a portion of an
immunoglobulin comprising a hinge region and a constant domain of a
mammalian immunoglobulin heavy chain. The portion or the IgG is fused at
its C-terminus with a polypeptide comprising a tailpiece from the
C-terminus of the heavy chain of an IgA antibody ara tailpiece from a
C-terminus of the heavy chain of an IgM antibody. Also disclosed herein
are methods for using these CD4 fusion proteins.
Type: Grant
Filed: October 24, 2002
Date of Patent: May 6, 2008
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
HIV related peptides
Patent number: 6911527
Abstract: This invention is the discovery of novel specific epitopes
and antibodies associated with long term survival of HIV-1 infections.
These epitopes and antibodies have use in preparing vaccines for
preventing HIV-1 infection or for controlling progression to AIDS.
Type: Grant
Filed: January 7, 2000
Date of Patent: June 28, 2005
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci
Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
Publication number: 20040265306
Abstract: Novel recombinant polypeptides are disclosed herein that
include a CD4 polypeptide ligated at its C-terminus with a portion of an
immunoglobulin comprising a hinge region and a constant domain of a
mammalian immunoglobulin heavy chain. The portion of the IgG is fused at
its C-terminus with a polypeptide comprising a tailpiece from the
C-terminus of the heavy chain of an IgA antibody or a tailpiece from a
C-terminus of the heavy chain of an IgM antibody. Also disclosed herein
are methods for using these CD4-fusion proteins.
Type: Application
Filed: July 27, 2004
Publication date: December 30, 2004
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
Immunologic enhancement with intermittent interleukin-2 therapy
Publication number: 20030180254
Abstract: A method for activating a mammalian immune system entails a
series of IL-2 administrations that are effected intermittently over an
extended period. Each administration of IL-2 is sufficient to allow
spontaneous DNA synthesis in peripheral blood or lymph node cells of the
patient to increase and peak, and each subsequent administration
follows the preceding administration in the series by a period of time
that is sufficient to allow IL-2 receptor expression in peripheral or
lymph node blood of the patient to increase, peak and then decrease to
50% of peak value. This intermittent IL-2 therapy can be combined with
another therapy which targets a specific disease state, such as an
anti-retroviral therapy comprising, for example, the administration of
AZT, ddI or interferon alpha. In addition, IL-2 administration can be
employed to facilitate in situ transduction of T cells in the context of
gene therapy.
Type: Application
Filed: January 23, 2003
Publication date: September 25, 2003
Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
Immunologic enhancement with intermittent interleukin-2 therapy
Patent number: 6548055
Abstract: A method for activating a mammalian immune system entails a
series of IL-2 administrations that are effected intermittently over an
extended period. Each administration of IL-2 is sufficient to allow
spontaneous DNA synthesis in peripheral blood or lymph node cells of the
patient to increase and peak, and each subsequent administration
follows the preceding administration in the series by a period of time
that is sufficient to allow IL-2 receptor expression in peripheral or
lymph node blood of the patient to increase, peak and then decrease to
50% of peak value. This intermittent IL-2 therapy can be combined with
another therapy which targets a specific disease state, such as an
anti-retroviral therapy comprising, for example, the administration of
AZT, ddI or interferon alpha. In addition, IL-2 administration can be
employed to facilitate in situ transduction of T cells in the context of
gene therapy.
Type: Grant
Filed: August 9, 2000
Date of Patent: April 15, 2003
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
Immunologic enhancement with intermittent interleukin-2 therapy
Patent number: 6190656
Abstract: A method for activating a mammalian immune system entails a
series of IL-2 administrations that are effected intermittently over an
extended period. Each administration of IL-2 is sufficient to allow
spontaneous DNA synthesis in peripheral blood or lymph node cells of the
patient to increase and peak, and each subsequent administration
follows the preceding administration in the series by a period of time
that is sufficient to allow IL-2 receptor expression in peripheral or
lymph node blood of the patient to increase, peak and then decrease to
50% of peak value. This intermittent IL-2 therapy can be combined with
another therapy which targets a specific disease state, such as an
anti-retroviral therapy comprising, for example, the administration of
AZT, ddI or interferon alpha. In addition, IL-2 administration can be
employed to facilitate in situ transduction of T cells in the context of
gene therapy.
Type: Grant
Filed: September 2, 1997
Date of Patent: February 20, 2001
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
Immunologic enhancement with intermittent interleukin-2 therapy
Patent number: 5696079
Abstract: A method for activating a mammalian immune system entails a
series of IL-2 administrations that are effected intermittently over an
extended period. Each administration of IL-2 is sufficient to allow
spontaneous DNA synthesis in peripheral blood or lymph node cells of the
patient to increase and peak, and each subsequent administration
follows the preceding administration in the series by a period of time
that is sufficient to allow IL-2 receptor expression in peripheral or
lymph node blood of the patient to increase, peak and then decrease to
50% of peak value. This intermittent IL-2 therapy can be combined with
another therapy which targets a specific disease state, such as an
anti-retroviral therapy comprising, for example, the administration of
AZT, ddI or interferon alpha. In addition, IL-2 administration can be
employed to facilitate in situ transduction of T cells in the context of
gene therapy.
Type: Grant
Filed: May 26, 1995
Date of Patent: December 9, 1997
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
